Clinical trials: Chemotherapeutic Agent Toxicity
Breast Neoplasms, HER2/Neu Positive
Tolerability of the Combination of Lapatinib and Trastuzumab in Adults Age 60 or Older With HER2 Positive Locally Advanced or Metastatic Breast Cancer
This phase II trial studies the side effects and how well lapatinib ditosylate and trastuzumab work in treating older patients with human epidermal growth factor receptor 2 (HER2)-positive breast cancer that has spread from where…
- Conditions
- Breast Neoplasms, HER2/Neu Positive, Geriatric Health Services
- Trial name
- NCT01273610
- Testing
- Lapatinib, Trastuzumab, laboratory biomarker analysis
- Where
- 8 sites in United States
- Volunteers
- 40 people
- Sponsor
- City of Hope Medical Center
Breast Cancer, Chemotherapeutic Agent Toxicity
G-CSF in Preventing Neutropenia in Women Receiving Chemotherapy for Breast Cancer
RATIONALE: G-CSF may prevent or reduce febrile neutropenia in women receiving chemotherapy for breast cancer. It is not yet known which G-CSF regimen is more effective in preventing neutropenia.
- Conditions
- Breast Cancer, Chemotherapeutic Agent Toxicity, Neutropenia
- Trial name
- NCT00771433
- Testing
- filgrastim
- Where
- France
- Volunteers
- 120 people
- Sponsor
- Centre Francois Baclesse
Cardiotoxicity, Chemotherapeutic Toxicity
Prevention of Chemotherapy-induced Cardiotoxicity in High-risk Patients
In cancer patients, the increase of troponin I soon after chemotherapy is a strong predictor of left ventricular dysfunction and poor cardiologic outcome.
- Trial name
- NCT00292526
- Testing
- Enalapril
- Where
- Italy
- Volunteers
- 114 people
- Sponsor
- European Institute of Oncology
Chemotherapeutic Agent Toxicity, Mucositis
Selenomethionine in Reducing Mucositis in Patients With Locally Advanced Head and Neck Cancer Who Are Receiving Cisplatin and Radiation Therapy
This randomized phase II trial is studying how well selenomethionine (SLM) works in reducing mucositis in patients with locally advanced head and neck cancer who are receiving cisplatin and radiation therapy.
- Conditions
- Chemotherapeutic Agent Toxicity, Mucositis, Radiation Toxicity, Stage III Squamous Cell Carcinoma of the Hypopharynx
- Trial name
- NCT01682031
- Testing
- selenomethionine, cisplatin, radiation therapy
- Where
- 2 sites in United States, New Zealand
- Volunteers
- 18 people
- Sponsor
- Roswell Park Cancer Institute
Chemotherapeutic Agent Toxicity, Neurotoxicity
Electrical Stimulation Therapy Using the MC5-A Scrambler in Reducing Peripheral Neuropathy Caused by Chemotherapy
RATIONALE: Electronic stimulation using a MC5-A Scrambler may help relieve pain in patients who develop peripheral neuropathy while undergoing chemotherapy treatments for cancer.
- Conditions
- Chemotherapeutic Agent Toxicity, Neurotoxicity, Pain, Peripheral Neuropathy
- Trial name
- NCT00952848
- Testing
- questionnaire administration, Sensory Neuropathy Scale instrument, Quality of Life instrument
- Volunteers
- 18 people
- Sponsor
- Virginia Commonwealth University
Chemotherapeutic Agent Toxicity, Pain
Cryotherapy in Preventing Peripheral Neuropathy and Nail Toxicity in Patients With Breast Cancer Who Are Receiving Paclitaxel
RATIONALE: Cryotherapy may help prevent peripheral neuropathy or nail toxicity in patients receiving chemotherapy. PURPOSE: This clinical trial studies cryotherapy in preventing peripheral neuropathy and nail toxicity in patients…
- Conditions
- Chemotherapeutic Agent Toxicity, Pain, Peripheral Neuropathy, Recurrent Breast Cancer
- Trial name
- NCT01243541
- Testing
- cryotherapy, questionnaire administration, quality-of-life assessment
- Where
- United States
- Volunteers
- 33 people
- Sponsor
- Northwestern University
Breast Cancer, Chemotherapeutic Agent Toxicity
Nicotine Patches in Reducing Hand-Foot Syndrome in Patients Who Are Receiving Capecitabine For Metastatic Breast Cancer
RATIONALE: Nicotine patches may reduce hand-foot syndrome in patients receiving capecitabine for metastatic breast cancer. It is not yet known which nicotine patch regimen may be more effective in reducing hand-foot syndrome.
- Conditions
- Breast Cancer, Chemotherapeutic Agent Toxicity, Palmar-plantar Erythrodysesthesia
- Trial name
- NCT00751101
- Testing
- Nicotine patch
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- University of California, San Francisco
Chemotherapeutic Agent Toxicity, Neuropathy
Glutathione in Preventing Peripheral Neuropathy Caused by Paclitaxel and Carboplatin in Patients With Ovarian Cancer, Fallopian Tube Cancer, and/or Primary Peritoneal Cancer
This randomized phase III trial is studying glutathione to see how well it works in preventing peripheral neuropathy caused by paclitaxel and carboplatin in patients with ovarian cancer, fallopian tube cancer, and/or primary…
- Conditions
- Chemotherapeutic Agent Toxicity, Neuropathy, Neurotoxicity Syndrome, Pain
- Trial name
- NCT02311907
- Testing
- Carboplatin, Glutathione, Laboratory Biomarker Analysis
- Where
- 390 sites in United States
- Volunteers
- 195 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Breast Cancer, Cardiotoxicity
Understanding CARdiac Events in Breast Cancer
In Ireland, over 3,000 patients are diagnosed with breast cancer annually, and 1 in 9 Irish women will be diagnosed with breast cancer in their lifetime.
- Conditions
- Breast Cancer, Cardiotoxicity, Cardiomyopathies, Chemotherapeutic Toxicity
- Trial name
- UCARE (NCT05921279)
- Where
- 4 sites in Ireland
- Volunteers
- 100 people
- Sponsor
- National University of Ireland, Galway, Ireland
Chemotherapeutic Agent Toxicity, Neutropenia
G-CSF in Preventing Neutropenia in Patients With Solid Tumors Who Are Receiving Chemotherapy
RATIONALE: Colony-stimulating factors, such as G-CSF, may increase the number of white blood cells found in bone marrow or peripheral blood and may prevent persistent neutropenia in patients receiving chemotherapy.
- Conditions
- Chemotherapeutic Agent Toxicity, Neutropenia, Unspecified Adult Solid Tumor, Protocol Specific
- Trial name
- NCT00770172
- Testing
- filgrastim
- Where
- France
- Volunteers
- 140 people
- Sponsor
- Centre Francois Baclesse
Chemotherapeutic Agent Toxicity, Infection
Using Whole-Person-Care Guide in Patients Receiving Care for Cancer or Complications From Cancer Treatment
RATIONALE: Gathering information about patients with cancer and cancer-related conditions may help doctors learn more about a patient's needs and help doctors plan the best treatment.
- Conditions
- Chemotherapeutic Agent Toxicity, Infection, Malnutrition, Musculoskeletal Complications
- Trial name
- NCT00608738
- Testing
- informational intervention, medical chart review, questionnaire administration
- Volunteers
- 750 people
- Sponsor
- Northwestern University
Kidney Injury, Antineoplastics Toxicity
Immune Checkpoint Inhibitors Nephrotoxicity
In recent years, immunotherapy has been postulated as one of the most effective strategy in the fight against cancer. The greatest success in this field has been achieved through the inhibition of molecules involved in the brake…
- Trial name
- NCT04902846
- Testing
- Early kidney damage biomarkers, Predisposition to kidney injury biomarkers
- Where
- 2 sites in Spain
- Volunteers
- 220 people
- Sponsor
- R. Laura Vicente Vicente
Breast Cancer, Chemotherapeutic Agent Toxicity
L-Carnitine L-Tartrate in Preventing Peripheral Neuropathy Caused By Chemotherapy in Women With Metastatic Breast Cancer
RATIONALE: L-carnitine L-tartrate may prevent peripheral neuropathy caused by chemotherapy. PURPOSE: This randomized clinical trial is studying how well L-carnitine L-tartrate works in preventing peripheral neuropathy caused by…
- Conditions
- Breast Cancer, Chemotherapeutic Agent Toxicity, Neurotoxicity
- Trial name
- NCT00754767
- Testing
- L-carnitine L-tartrate
- Where
- 2 sites in United States
- Volunteers
- 2 people
- Sponsor
- HealthPartners Institute
Chemotherapeutic Agent Toxicity, Multiple Myeloma
Glutamine in Preventing Peripheral Neuropathy in Patients With Multiple Myeloma Receiving Bortezomib
This randomized phase II trial studies glutamine in preventing peripheral neuropathy in patients with multiple myeloma who are receiving bortezomib.
- Conditions
- Chemotherapeutic Agent Toxicity, Multiple Myeloma, Peripheral Neuropathy
- Trial name
- NCT01783522
- Testing
- glutamine, quality-of-life assessment
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Beth Faiman
Chemotherapeutic Agent Toxicity, Colorectal Cancer
Biomarkers in Predicting Neurotoxicity in Patients With Colorectal Cancer Receiving Oxaliplatin
RATIONALE: Studying samples of blood in the laboratory from patients receiving oxaliplatin for cancer may help doctors learn more about changes that occur in DNA and identify biomarkers related to neurotoxicity.
- Conditions
- Chemotherapeutic Agent Toxicity, Colorectal Cancer, Neurotoxicity
- Trial name
- NCT00884767
- Testing
- FOLFOX regimen, fluorouracil, leucovorin calcium
- Where
- France
- Volunteers
- 206 people
- Sponsor
- Institut Cancerologie de l'Ouest
Chemotherapeutic Toxicity, Chemotherapeutic Agent Toxicity
Diminish Chemotherapy Related Side Effects Through Patient Education
Currently, there is a lack of patient education materials regarding cytotoxic chemotherapy side effects, research supported treatments, and the utilization of CAM by cancer patients at Penn State Cancer Institute.
- Conditions
- Chemotherapeutic Toxicity, Chemotherapeutic Agent Toxicity, Chemotherapy Effect
- Trial name
- D-CRSE (NCT04694794)
- Testing
- Educational Brochure
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- Milton S. Hershey Medical Center
Cardiotoxicity, Heart Failure
MyoStrain CMR for the Detection of Cardiotoxicity
The Prefect Pilot Study evaluates the use of the EC approved MyoStrain SENC CMR Imaging System to detect cardiotoxicity from drugs used to treat cancer (e.g. Breast Cancer and Lymphomas).
- Conditions
- Cardiotoxicity, Heart Failure, Chemotherapeutic Toxicity
- Trial name
- Prefect (NCT03543228)
- Testing
- MyoStrain
- Where
- Germany
- Volunteers
- 63 people
- Sponsor
- Myocardial Solutions
Solid Carcinoma, 5-Fluorouracil Toxicity
Prevention of Chest Pain in Chemo-treated Cancer Patients
This is a prospective, exploratory, randomised clinical trial. Patients with diagnosed cancer that are to be treated with 5-fluorouracil (5-FU) will be randomised into standard oncological treatment or a cardiological assessment…
- Conditions
- Solid Carcinoma, 5-Fluorouracil Toxicity, Cardiotoxicity, Chemotherapeutic Toxicity
- Trial name
- CATCH (NCT03486340)
- Testing
- Cardiologic assessment
- Where
- Denmark
- Volunteers
- 218 people
- Sponsor
- Vejle Hospital